MedTrace Logo

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

NCT07237516 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2026-03-17

No results posted yet for this study

Summary

The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed Zymfentra (IFX-dyyb as part of their regular medical care for CD or UC will answer online survey questions about their bowel habits for 1 year.

Conditions

  • Ulcerative Colitis (UC)
  • Crohn's Disease (CD)
  • Indeterminate Colitis
  • Inflammatory Bowel Disease (IBD)

Sponsors & Collaborators

  • University of North Carolina, Chapel Hill

    lead OTHER

  • Celltrion

    collaborator INDUSTRY

Principal Investigators

  • Hans Herfarth, MD, PhD · University of North Carolina

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-20
Primary Completion
2028-11-03
Completion
2028-11-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07237516 on ClinicalTrials.gov